^
Association details:
| Biomarker: | SMARCB1 deletion |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | SHR-2554 (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1941P - Preliminary efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase II trial
Published date:
10/16/2023
Excerpt:
Between Jul 2021 and Dec 2022, a total of 9 pts were enrolled and received SHR-2554...Loss of INI1 was confirmed in 6 (66.7%) pts. 5 (55.6%) pts remained progression-free at 12 weeks, which allowing to move on to stage 2. Based on investigator assessments, one (11.1%) of 9 pts had a confirmed partial response at data cutoff. The median progression-free survival was 3.8 months (95% CI: 1.2–NA)...Based on investigator assessments, one (11.1%) of 9 pts had a confirmed partial response at data cutoff. The median progression-free survival was 3.8 months (95% CI: 1.2–NA)...
